IONS

IonisC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$106.24

+45.6% vs current

Most likely

Base case

60%

Probability

Target price

$89.24

+22.3% vs current

B-

Bear case

20%

Probability

Target price

$63.74

-12.6% vs current

AI sentiment snapshot

Latest data as of 2026-02-06

AI commentary

Neutral-to-cautious: the base target sits near the current anchor, indicating limited near-term upside. Wide analyst high/low dispersion points to event-driven volatility tied to clinical readouts and partner outcomes; market likely to await concrete results or consensus revisions before re-rating.

RankAlpha Sentiment AI - 2026-02-06

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-30eventAnalyst consensus update windowMedium impact

Periodic analyst target revisions and model updates (consensus currently mixed) may shift near-term sentiment; date set conservatively as window end given no single disclosure [#SERP-1], [#SERP-2].

2026-05-07catalystNext quarterly results (estimated)High impact

Market reaction to the upcoming quarterly results could reprice shares; date is estimated due to no confirmed IR release — assumption: typical company reporting cadence [#SERP-2].

2027-02-06catalystPipeline/readout or regulatory milestone (potential)High impact

Late-stage program readouts or regulatory decisions could drive multi-quarter revaluation; timing uncertain — conservative one-year horizon used for planning.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-02-06 • Updated nightlySource: Internal modelMethodology